Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Abpro Holdings, Inc.
SIC 2836 · Biological Products, (No Diagnostic Substances)
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Abpro Holdings, Inc.
SIC 2836 · Biological Products, (No Diagnostic Substances)
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Abpro Holdings, Inc.
SIC 2836 · Biological Products, (No Diagnostic Substances)
Support
about
terms
$
ABPWW
Abpro Holdings, Inc.
CIK:
0001893219
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:
Research and development
$ 9
$ 313
$ 22
$ 638
General and administrative
1,166
1,948
2,086
4,581
Total operating expenses
1,175
2,261
2,108
5,219
Loss from operations
(1,175)
(2,261)
(2,108)
(5,219)
Other (expense) income:
Gain on settlement of liabilities
219
200
219
200
Other income
2
Interest expense
(23)
(174)
(46)
(911)
Interest income
39
6
61
24
Change in fair value of forward purchase agreement asset
(23)
Change in fair value of SEPA put rights asset
(19)
(96)
(175)
Change in fair value of embedded derivative liability
(592)
(623)
Loss on settlement of convertible notes
(144)
(144)
Total other income (expense), net
235
(723)
140
(1,652)
Net loss
$ (940)
$ (2,984)
$ (1,968)
$ (6,871)
Net loss per share, basic
$ (0.16)
$ (1.56)
$ (0.38)
$ (3.8)
Net loss per share, diluted
$ (0.16)
$ (1.56)
$ (0.38)
$ (3.8)
Weighted average shares outstanding - basic (in Shares)
5,896,048
1,917,246
5,197,159
1,807,937
Weighted average shares outstanding - diluted (in Shares)
5,896,048
1,917,246
5,197,159
1,807,937
v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows from Operating Activities:
Net loss
$ (1,968)
$ (6,871)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
5
14
Share-based compensation
510
872
Amortization of operating lease right-of-use assets
281
Noncash interest expense
714
Loss on settlement of convertible notes
144
Gain on settlement of liabilities (Note 7)
(219)
(200)
Amortization of debt discount
133
Change in fair value of forward purchase agreement asset
23
Change in fair value of SEPA put rights asset
96
175
Change in fair value of embedded derivative liability
623
Changes in operating assets and liabilities:
Accounts receivable
183
(19)
Prepaid expenses and other current assets
(308)
161
Accounts payable
(945)
1,328
Accrued expenses
(488)
317
Income taxes payable
59
Operating lease liability
(306)
Net cash used in operating activities
(3,134)
(2,552)
Cash Flows from Financing Activities:
Gross proceeds from issuance of Advance Shares
7,264
Proceeds from Convertible Notes
1,840
Proceeds from settlement of Forward Purchase Agreement
132
Payments on Note payable
(383)
Payments on Notes payable, related parties
(123)
Proceeds from Notes payable, related parties
147
Net cash provided by financing activities
7,288
1,589
Net change in cash and restricted cash
4,154
(963)
Cash and restricted cash - beginning of period
82
2,992
Cash and restricted cash - end of period
4,236
2,029
Supplemental disclosure of cash flow information and non-cash transactions:
Interest paid
13
19
Accrued issuance costs for Advance Shares
508
Common stock issued in settlement of convertible notes and embedded derivative liability
3,694
Fair value of common stock issued for services
161
Prepaid expenses financed through Note payable
553
As reported within the unaudited condensed consolidated balance sheets:
Cash
4,236
2,014
Restricted cash
15
Total cash and restricted cash as presented in the balance sheet
$ 4,236
$ 2,029
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:
Cash
$ 4,236
$ 67
Accounts receivable
183
Prepaid expenses and other current assets
788
480
Security deposits
55
55
SEPA put rights asset
96
Restricted cash
15
Total current assets
5,079
896
Patents, net
162
167
Total assets
5,241
1,063
Current liabilities:
Accounts payable
4,159
5,323
Accrued expenses
3,895
3,875
Total current liabilities
8,225
9,345
Commitments and Contingencies (Note 7)
Stockholders’ deficit:
Preferred stock, $0.0001 par value, 1,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.0001 par value; 110,000,000 shares authorized; 5,896,048 and 2,733,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
1
Additional paid-in capital
117,429
110,164
Accumulated deficit
(120,963)
(118,995)
Total Abpro Holdings, Inc.’s stockholders’ deficit
(3,533)
(8,831)
Non-controlling interest
549
549
Total stockholders’ deficit
(2,984)
(8,282)
Total liabilities and stockholders’ deficit
5,241
1,063
Related Party
Current liabilities:
Notes payable, current – related parties
$ 171
$ 147